ArticleJAMA cardiology2017
Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans.
Article in JAMA cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Impact of manufacturer-initiated list price reduction on patient out-of-pocket costs forJournal of managed care & specialty pharmacy · 2024Article
- 2024 Egyptian consensus statement on the role of non-statin therapies for LDL cholesterol lowering in different patient risk categories.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Review
- Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease.Journal of the American Geriatrics Society · 2023Article
- The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice.Current cardiology reports · 2021Review
- Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease.Journal of clinical medicine · 2021Article
- Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.JAMA network open · 2021Article
- Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.JAMA network open · 2020Article
- Article
- PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.Journal of the American Heart Association · 2019 · on this mapArticle
- What are the benefits and drawbacks of statins in carotid artery disease? A perspective review.Expert review of cardiovascular therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.